Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkaf093 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Jung Ae Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States. Hauptthemen laut MEDLINE: Neoplasms, Cancer Survivors, Survivors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.
Abstract (Originalsprache)
Background
Comorbidities worsen cancer survival, but patterns of preexisting and new-onset comorbidities among cancer survivors are unknown.
Methods
We investigated self-reported and clinically diagnosed comorbidity among cancer survivors in the All-of-Us program’s national database. Eight highly prevalent comorbidities were identified using self-reported data from the personal health history survey among cancer survivors (n = 20 534) and noncancer adults (n = 113 628) and validated among cancer survivors (n = 26 978) using data from electronic health records (EHRs). Among 5-year survivors (n = 9174) documented in EHR, we further estimated the incidence of new-onset comorbidities.
Results
The most prevalent comorbidities identified in personal health history data were hypertension (40.5%), osteoarthritis (28.4%), depression (28.0%), and obesity (23.2%). EHR data identified preexisting comorbidities: hypertension (43.3%), osteoarthritis (29.4%), depression (19.4%), and obesity (19.1%). During 5-year survival, more than 50% of cancer survivors developed at least one new comorbidity, and more than 25% developed two or more. The onset of new comorbidities showed a sharp increase in the first-year postdiagnosis. Incidence rates varied by age, race, and ethnicity.
Conclusion
Future research is needed to develop effective strategies to prevent new-onset comorbidities during and after cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States.
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, United States.
- Department of Cancer Epidemiology and Prevention Research, Cancer Care, Alberta, Canada.
ORCID-Profile: Jung Ae Lee, Daniel J Amante, Ben S Gerber, Lin Yang
Förderung
- NIH HHS
Zitieren
APA
Lee, J. A., Pakpahan, R., Amante, D. J., Gerber, B. S., & Yang, L. (2025). Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf093
Vancouver
Lee JA, Pakpahan R, Amante DJ, Gerber BS, Yang L. Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf093
BibTeX
@article{Lee2025,
author = {Lee, Jung Ae and Pakpahan, Ratna and Amante, Daniel J and Gerber, Ben S and Yang, Lin},
title = {Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkaf093}
}
EUVIMED